TScan Therapeutics (NASDAQ: TCRX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 15.38 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $982.000 thousand which missed the analyst consensus estimate of $2.500 million by 60.72 percent. This is a 54.77 percent decrease over sales of $2.171 million the same period last year.